Kimihiro Shimizu1, Yoichi Ohtaki2, Kenji Suzuki3, Hiroshi Date4, Motohiro Yamashita5, Toshihiko Iizasa6, Hiroyuki Ito7, Kenichi Yoshimura8, Morihito Okada9, Masayuki Chida10. 1. Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Maebashi, Gunma, Japan; Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. Electronic address: kmshimizu@gmail.com. 2. Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Maebashi, Gunma, Japan. 3. Department of General Thoracic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan. 4. Department of Thoracic Surgery, Kyoto University, Kyoto, Kyoto, Japan. 5. Division of General Thoracic Surgery, Shikoku Cancer Center, Matsuyama, Ehime, Japan. 6. Division of General Thoracic Surgery, Chiba Cancer Center, Chiba, Chiba, Japan. 7. Department of Thoracic Surgery, Kanagawa Cancer Center, Asahi-ku, Yokohama, Japan. 8. Innovative Clinical Research Center, Kanazawa University, Kanazawa, Ishikawa, Japan; Department of Biostatistics, Hiroshima University Hospital, Hiroshima University, Hiroshima, Hiroshima, Japan. 9. Department of Surgical Oncology, Hiroshima University, Hiroshima, Hiroshima, Japan. 10. Department of General Thoracic Surgery, Dokkyo Medical University, Mibu, Tochigi, Japan.
Abstract
BACKGROUND: The aim of this study was to describe the characteristics and outcomes of patients with non-small cell lung cancer undergoing salvage surgery after chemoradiotherapy, conventional external beam, stereotactic body radiotherapy, and ion beam radiotherapy. METHODS: We retrospectively evaluated patients who underwent salvage surgery between 2010 and 2016. Data on perioperative morbidity and mortality and patient outcomes were analyzed. RESULTS: In total, 156 patients were included; of those, 110 were categorized into category 1, chemoradiotherapy or conventional external beam; and 46 into category 2, stereotactic body radiotherapy or ion beam radiotherapy. Three-year overall survival (OS) and recurrence-free survival (RFS) in category 1 were 67.3% and 49.8%, respectively. In category 1, pathological nodal stage was an independent prognosticator of both OS (hazard ratio [HR] = 3.53, 95% confidence interval [CI], 1.05-11.83) and RFS (HR = 4.32, 95% CI, 1.32-14.14). In category 2, 3-year OS and RFS were 57.7% and 46.4%, respectively. Age 70 years and greater at initial treatment was the only independent prognosticator of OS (HR = 5.61; 95% CI, 1.44-21.87), whereas age at initial treatment (HR = 6.13; 95% CI, 1.38-27.12) and pathological nodal metastasis (HR = 3.84; 95% CI, 1.40-10.57) were independent prognosticators for RFS. Overall 30- and 90-day mortality were 0% and 0.9% in category 1 and 0% and 4.3% in category 2, respectively. CONCLUSIONS: Patients who undergo salvage surgery can have reasonable outcomes, and salvage surgery can be considered in selected patients.
BACKGROUND: The aim of this study was to describe the characteristics and outcomes of patients with non-small cell lung cancer undergoing salvage surgery after chemoradiotherapy, conventional external beam, stereotactic body radiotherapy, and ion beam radiotherapy. METHODS: We retrospectively evaluated patients who underwent salvage surgery between 2010 and 2016. Data on perioperative morbidity and mortality and patient outcomes were analyzed. RESULTS: In total, 156 patients were included; of those, 110 were categorized into category 1, chemoradiotherapy or conventional external beam; and 46 into category 2, stereotactic body radiotherapy or ion beam radiotherapy. Three-year overall survival (OS) and recurrence-free survival (RFS) in category 1 were 67.3% and 49.8%, respectively. In category 1, pathological nodal stage was an independent prognosticator of both OS (hazard ratio [HR] = 3.53, 95% confidence interval [CI], 1.05-11.83) and RFS (HR = 4.32, 95% CI, 1.32-14.14). In category 2, 3-year OS and RFS were 57.7% and 46.4%, respectively. Age 70 years and greater at initial treatment was the only independent prognosticator of OS (HR = 5.61; 95% CI, 1.44-21.87), whereas age at initial treatment (HR = 6.13; 95% CI, 1.38-27.12) and pathological nodal metastasis (HR = 3.84; 95% CI, 1.40-10.57) were independent prognosticators for RFS. Overall 30- and 90-day mortality were 0% and 0.9% in category 1 and 0% and 4.3% in category 2, respectively. CONCLUSIONS: Patients who undergo salvage surgery can have reasonable outcomes, and salvage surgery can be considered in selected patients.